group 2 products
- Guideline or reference source
- HCGMP Canada GMP guidelines 2009
- Definition
- Drugs listed in Schedule D to the Act and subject to Health Canada’s lot release programme which require the highest level assessment after the notice of compliance (NOC) has been issued. This assessment includes targeted testing, protocol review, and written approval for sale of each lot in Canada in the form of a release letter.
Send comments to info@qdossier.com Please read disclaimer before using Qsauri.